Cel-Sci Drug Could Be Used to Treat HPV-Induced Cervical Dysplasia in Women With HIV
Studies of an immunotherapy drug from Cel-Sci, a Vienna, Va.-based biopharmaceutical company, could lead to a new treatment for human papillomavirus-induced cervical dysplasia, a precursor to cervical cancer, in women with HIV, the Washington Post reports. Tests of the drug in five women demonstrated that the drug could eliminate HPV-induced cervical dysplasia in the majority of women. Approximately 120,000 to 140,000 American women are co-infected with HIV and HPV (Washington Post, 10/10).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.